|Baxter and Momenta Announce Collaboration; Bristol-Squibb and the Gladstone Enter Three-Year Discovery Partnership in Alzheimer’s Disease|
|By Staff and Wire Reports|
|Thursday, 22 December 2011 20:03|
Baxter International Inc. (NYSE:BAX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions. With this collaboration, Baxter will leverage its leading clinical development and biologic manufacturing expertise, global leadership in sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development.
Under the terms of the agreement, Baxter will make an upfront cash payment of $33 million to Momenta related to the collaboration for up to six follow-on biologic compounds. Baxter may make additional payments over the next several years for the development of the compounds, contingent upon the achievement of technical, development and regulatory milestones with respect to all six products.
"Baxter is an established leader in biologic treatments for a variety of diseases. As biologics have become an increasingly important part of patient care, the collaboration with Momenta allows us to tap both companies' expertise to expand access to these important therapies," said Ludwig Hantson, President of Baxter's BioScience business. "The collaboration complements Baxter's early-stage pipeline and allows the company to expand its leadership in biologics at a time when the global regulatory pathway for approval is becoming more clear."
"Momenta and Baxter share a common goal in this collaboration -- to create interchangeable biologic products by taking advantage of Momenta's innovative physicochemical and biologic characterization capabilities, coupled with a quality-by-design approach to process development," commented Craig Wheeler, President and CEO of Momenta. "We are thrilled to have Baxter as a partner. Baxter's global footprint and extensive development, manufacturing and commercial expertise are exactly what we need to succeed in building a leading follow-on biologics business."
Baxter and Momenta expect to close the transaction in the first quarter of 2012, subject to customary closing conditions including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Bristol-Myers Squibb Company (NYSE:BMY) and the Gladstone Institutes announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimers disease.
Under the agreement, Bristol-Myers Squibb will fund Gladstones research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cells internal skeleton and may help regulate the activity of brain cells. In Alzheimers disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.
Bristol-Myers Squibb is committed to helping patients address the unmet medical need for effective treatments across the Alzheimers disease continuum, from predementia to severe disease, by developing and studying a broad and diversified portfolio of compounds directed at multiple pathologies and different mechanisms, said Francis Cuss , MD, senior vice president, Discovery. By leveraging the cutting edge expertise of the Gladstone Institutes in Alzheimers disease we are hoping that the scientific innovation in drug development that often happens at the crossroads of different disciplines will lead to a better understanding of the role of Tau in Alzheimers disease and, potentially, lead to the identification of new therapies for the treatment of this serious disease.
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification of the granting of a Canadian patent with broad claims directed to: "METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM".
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that it has agreed to sell approximately $1.75 million of its common stock and warrants to six institutional investors in a private placement transaction.
Bristol-Myers Squibb Company (NYSE: BMY) and the Gladstone Institutes today announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer’s disease.
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Roche has submitted a Marketing Authorization Application (MAA) for vismodegib (GDC-0449, RG3616) to the European Medicines Agency (EMA). The MAA is currently under review for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of an international Phase 2b clinical trial to evaluate the preliminary efficacy and safety of its tumor-targeting doxorubicin conjugate INNO-206 in patients with late-stage soft tissue sarcoma.
Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 5, 2012, in New York, NY.
Neogen Corporation (NASDAQ: NEOG) announced today that its revenues for the second quarter of FY 2012, which ended Nov. 30, increased 2.2% from the previous year's second quarter to $44,891,000.
Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions including encapsulation of live cells and services through their associate SG Austria, released information today about the therapeutic potential of the patent for treatment of HIV and Ebola viruses, Bird flu, SARS, and other infectious diseases.
SDIX™ (NASDAQ: SDIX), today announced the publication of a comparative, in-depth study characterizing the strengths of its innovative DNA-immunization based Genomic Antibody Technology™, or GAT™.
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, today announced that Walt Woltosz, chairman and chief executive officer, will present at the Sidoti & Company Semi-Annual New York Micro-Cap Conference at 1:20 p.m. ET on Monday, January 9, 2012 in the Estate 3/Alvin room at the Grand Hyatt New York Hotel.
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) announced that the hearing on the Company’s claims in the demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceuticals Company Limited, or Takeda, dated October 29, 2004, have concluded within the expected timeframe and we look forward to the arbitrators’ decision in the first quarter of 2012.
Synageva BioPharma Corp., (“Synageva”) (NASDAQ:GEVA) a clinical stage biopharmaceutical company developing therapeutic products for rare disorders announced that it has completed enrollment in the first clinical trial of enzyme replacement for Lysosomal Acid Lipase (LAL) Deficiency.
TechsLoanstar, Inc. (PINKSHEETS: TCLN) (OTCQB: TCLN) and Quture, Inc. ("Quture") announce the commencement of the Demonstration Project at Niagara Memorial Medical Center, Niagara Falls, New York (NFMMC). Quture/TCLN continues to prepare to launch its new "transformative" and "disruptive" clinical performance measurement tool to improve health care while reducing costs.
Thomson Reuters (TSX: TRI) (NYSE: TRI), the world's leading source of intelligent information for businesses and professionals, today announced that it has suspended the divestiture process for its Healthcare business.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Friday, January 6, 2012 at 10:00 a.m. EST (7:00 a.m. PST) to announce 2012 financial guidance.
Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (PINKSHEETS:VRSEF) (FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in skin cancer detection technology, has begun the process to obtain US Food and Drug Administration (FDA) approval for Verisante Aura.
VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has filed a further patent application building on its Nucleosomics technology platform.